Huang Lei, Li Tong, Xu Lei, Hu Xiao-Min, Duan Da-Wei, Li Zhi-Bo, Gao Xin-Jing, Li Jun, Wu Peng, Liu Ying-Wu
Department of Heart Center, Tianjin third central hospital, Tianjin, China (mainland).
Department of Critical Care Medicine, Tianjin third central hospital, Tianjin, China (mainland).
Med Sci Monit. 2017 Feb 10;23:741-750. doi: 10.12659/msm.900005.
BACKGROUND No definitive conclusions have been drawn from the available data about the utilization of extracorporeal membrane oxygenation (ECMO) to treat severe acute respiratory distress syndrome (ARDS). The aim of this study was to review our center's experience with ECMO and determine predictors of outcome from our Chinese center. MATERIAL AND METHODS We retrospectively analyzed a total of 23 consecutive candidates who fulfilled the study entry criteria between January 2009 and December 2015. Detailed clinical data, ECMO flow, and respiratory parameters before and after the introduction of ECMO were compared among in-hospital survivors and nonsurvivors; factors associated with mortality were investigated. RESULTS Hemodynamics and oxygenation parameters were significantly improved after ECMO initiation. Thirteen patients survived to hospital discharge. Univariate correlation analysis demonstrated that APACHE II score (r=-0.463, p=0.03), acute kidney injury (r=-0.574, p=0.005), membrane oxygenator replacement (r=-0.516, p=0.014) and total length of hospital stay (r=0.526, p=0.012) were significantly correlated with survival to hospital discharge, and that the evolution of the levels of urea nitrogen, platelet, and fibrinogen may help to determine patient prognosis. Sixteen patients referred for ECMO from an outside hospital were successfully transported to our institution by ambulance, including seven transported under ECMO support. The survival rate of the ECMO-transport group was comparable to the conventional transport or the non-transport group (both p=1.000). CONCLUSIONS ECMO is an effective alternative option for severe ARDS. APACHE II score on admission, onset of acute kidney injury, and membrane oxygenator replacement, and the evolution of levels of urea nitrogen, platelet, and fibrinogen during hospitalization may help to determine the in-hospital patient prognosis. By establishing a well-trained mobile ECMO team, a long-distance, inter-hospital transport can be administered safely.
背景 关于使用体外膜肺氧合(ECMO)治疗重症急性呼吸窘迫综合征(ARDS),现有数据尚未得出明确结论。本研究旨在回顾我们中心使用ECMO的经验,并确定来自我们中国中心的预后预测因素。材料与方法 我们回顾性分析了2009年1月至2015年12月期间共23例符合研究纳入标准的连续患者。比较了院内存活者和非存活者的详细临床数据、ECMO流量以及引入ECMO前后的呼吸参数;调查了与死亡率相关的因素。结果 启动ECMO后,血流动力学和氧合参数显著改善。13例患者存活至出院。单因素相关性分析表明,急性生理与慢性健康状况评分系统II(APACHE II)评分(r = -0.463,p = 0.03)、急性肾损伤(r = -0.574,p = 0.005)、膜式氧合器更换(r = -0.516,p = 0.014)以及住院总时长(r = 0.526,p = 0.012)与存活至出院显著相关,并且尿素氮、血小板和纤维蛋白原水平的变化可能有助于确定患者预后。16例从外院转诊接受ECMO治疗的患者通过救护车成功转运至我院,其中7例在ECMO支持下转运。ECMO转运组的存活率与传统转运组或非转运组相当(p均 = 1.000)。结论 ECMO是重症ARDS的一种有效替代选择。入院时的APACHE II评分、急性肾损伤的发生、膜式氧合器更换以及住院期间尿素氮、血小板和纤维蛋白原水平的变化可能有助于确定院内患者的预后。通过建立一支训练有素的移动ECMO团队,可以安全地进行长途院际转运。